Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy

BACKGROUND: Uncommon response during immunotherapy is a new challenging issue in oncology practice. Recently, new criteria for evaluation of response to immunotherapy immune response evaluation criteria in solid tumors (iRECIST) were accepted. According to iRECIST, worsening of performance status (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrankar, Martina, Unk, Mojca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287173/
https://www.ncbi.nlm.nih.gov/pubmed/30367809
http://dx.doi.org/10.2478/raon-2018-0037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287173/
https://www.ncbi.nlm.nih.gov/pubmed/30367809
http://dx.doi.org/10.2478/raon-2018-0037

Ejemplares similares